[go: up one dir, main page]

NO20081796L - Sulfonylpyrrolhydrokloridsalter som histondeacetylaseinhibitorer - Google Patents

Sulfonylpyrrolhydrokloridsalter som histondeacetylaseinhibitorer

Info

Publication number
NO20081796L
NO20081796L NO20081796A NO20081796A NO20081796L NO 20081796 L NO20081796 L NO 20081796L NO 20081796 A NO20081796 A NO 20081796A NO 20081796 A NO20081796 A NO 20081796A NO 20081796 L NO20081796 L NO 20081796L
Authority
NO
Norway
Prior art keywords
sulfonylpyrrole
salts
histone deacetylase
deacetylase inhibitors
acrylamide
Prior art date
Application number
NO20081796A
Other languages
English (en)
Inventor
Thomas Beckers
Rolf-Peter Hummel
Thomas Maier
Thomas Bar
Martin Feth
Matthias Mueller
Original Assignee
Nycomed Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nycomed Gmbh filed Critical Nycomed Gmbh
Publication of NO20081796L publication Critical patent/NO20081796L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • C07D207/48—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Forbindelser med en bestemt formel I, hvor R1, R2, R3, R4, R5. R6 og R7 har betydningene indikert i beskrivelsen, samt salter derav, er nye effektive HDAC-inhibitorer. I mer detalj vedrører denne oppfinnelsen salter av en forbindelse valgt fra (E)-N-hydroksy-3-(1-[4-(([2-(iH-indoi-2-yl)-etyl]-metyi- amino)-metyl)-benzensulfonyl]-1H-pyrroi-3-yl)-akrylamid, (E)-3-[i-(4-dimetyiaminometyl- benzensulfonyl)-1H-pyrrol-3-yl]-N-hydroksy-akrylamid og (E)-N-hydroksy-3-[l-(5-pyridin-2-yl-tiofen-2-sulfonyl)-lH-pyrrol-3-yl]-akrylamid med saltsyre, deres hydrater og krystallinske former av disse saltene eller hydratene.
NO20081796A 2005-09-21 2008-04-14 Sulfonylpyrrolhydrokloridsalter som histondeacetylaseinhibitorer NO20081796L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05108716 2005-09-21
PCT/EP2006/066189 WO2007039403A1 (en) 2005-09-21 2006-09-08 Sulphonylpyrrole hydrochloride salts as histone deacetylases inhibitors

Publications (1)

Publication Number Publication Date
NO20081796L true NO20081796L (no) 2008-04-17

Family

ID=35810290

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20081796A NO20081796L (no) 2005-09-21 2008-04-14 Sulfonylpyrrolhydrokloridsalter som histondeacetylaseinhibitorer

Country Status (16)

Country Link
US (1) US8188138B2 (no)
EP (1) EP1928826B1 (no)
JP (1) JP5305909B2 (no)
KR (1) KR101314158B1 (no)
CN (1) CN101287706A (no)
AR (1) AR055647A1 (no)
AU (1) AU2006298881A1 (no)
BR (1) BRPI0616040A2 (no)
CA (1) CA2622670A1 (no)
EA (1) EA018698B1 (no)
IL (1) IL189781A0 (no)
NO (1) NO20081796L (no)
NZ (1) NZ566073A (no)
TW (1) TWI382971B (no)
WO (1) WO2007039403A1 (no)
ZA (1) ZA200801351B (no)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE556713T1 (de) 1999-01-13 2012-05-15 Bayer Healthcare Llc Omega-carboxyarylsubstituierte-diphenyl- harnstoffe als p38-kinasehemmer
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
AU2003209116A1 (en) 2002-02-11 2003-09-04 Bayer Pharmaceuticals Corporation Aryl ureas with angiogenesis inhibiting activity
US7557129B2 (en) 2003-02-28 2009-07-07 Bayer Healthcare Llc Cyanopyridine derivatives useful in the treatment of cancer and other disorders
PT1636585E (pt) 2003-05-20 2008-03-27 Bayer Pharmaceuticals Corp Diarilureias com actividade inibidora de cinase
ES2430371T3 (es) * 2004-03-11 2013-11-20 4Sc Ag Sulfonilpirroles como inhibidores de HDAC
CA2564325A1 (en) 2004-04-30 2005-11-24 Bayer Pharmaceuticals Corporation Substituted pyrazolyl urea derivatives useful in the treatment of cancer
NZ566074A (en) * 2005-09-21 2011-08-26 4Sc Ag Novel sulphonylpyrroles as inhibitors of HDAC's
WO2008127659A2 (en) * 2007-04-13 2008-10-23 University Of Texas Southwestern Medical Center Combination therapy for cancer
EP2100878A1 (en) 2008-03-12 2009-09-16 4Sc Ag Novel method for the production of sulphonylpyrroles as HDAC inhibitors
EP2100882A1 (en) * 2008-03-12 2009-09-16 4Sc Ag (E) -N -(2-Amino-phenyl) -3-{1-[4-(1-methyl-1H-pyrazol-4-yl)- benzenesulfonyl]-1H-pyrrol-3-yl} -acrylamide salts
CA2735593C (en) 2008-09-03 2017-08-15 Repligen Corporation Compositions including 6-aminohexanoic acid derivatives as hdac inhibitors
US8957066B2 (en) 2011-02-28 2015-02-17 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
US10059723B2 (en) 2011-02-28 2018-08-28 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
JP6250403B2 (ja) 2011-02-28 2017-12-20 バイオマリン ファーマシューティカル インク ヒストン脱アセチル化酵素阻害剤
US9387209B2 (en) 2012-04-10 2016-07-12 Annji Pharmaceutical Co., Ltd. Histone deacetylases (HDACs) inhibitors
BR112015023399A8 (pt) 2013-03-15 2019-12-03 Biomarin Pharm Inc inibidores de hdac, seu uso e composição farmacêutica
PL3053578T3 (pl) * 2013-09-30 2021-06-14 Taiho Pharmaceutical Co., Ltd. Skojarzona terapia przeciwnowotworowa z zastosowaniem związku azabicyklicznego
ES2879294T3 (es) 2016-07-26 2021-11-22 Fresenius Kabi Oncology Ltd Formas polimórficas de Belinostat y procesos para la preparación de las mismas
CN110621317B (zh) 2017-05-16 2023-05-12 安基生技新药股份有限公司 组蛋白去乙酰化酶（hdacs）抑制剂
EP4079842A4 (en) * 2019-12-16 2024-01-24 EdiGene (GuangZhou) Inc. Small molecule compounds for amplifying hematopoietic stem cells, and combination thereof
US20230212129A1 (en) 2020-06-08 2023-07-06 Annji Pharmaceutical Co., Ltd. Quinazoline derivatives useful as selective hdac6 inhibitors

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4960787A (en) 1989-02-06 1990-10-02 Ciba-Geigy Corporation Certain pyrrolyl-substituted hydroxamic acid derivatives
KR100236806B1 (ko) 1991-12-10 2000-01-15 시오노 요시히코 방향족 설폰아미드계 하이드록삼산 유도체
CA2223154A1 (en) 1995-06-02 1996-12-05 G.D. Searle & Co. Heterocyclo substituted hydroxamic acid derivatives as cyclooxygenase-2 and 5-lipoxygenase inhibitors
GB9807354D0 (en) * 1998-04-07 1998-06-03 Glaxo Group Ltd Antiviral compound
US7141593B1 (en) * 1999-06-04 2006-11-28 Abbott Laboratories Pharmaceutical formulations
CA2391012A1 (en) 1999-11-23 2001-05-31 Merck & Co., Inc. Pyrazinone thrombin inhibitors
DK1233958T3 (da) 1999-11-23 2011-10-17 Methylgene Inc Hæmmere af histondeacetylase
US6521618B2 (en) 2000-03-28 2003-02-18 Wyeth 3-cyanoquinolines, 3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors
HUP0400446A2 (hu) * 2001-05-22 2004-09-28 Pfizer Products Inc. Azitromicin kristályformái
EP1431267A4 (en) 2001-08-09 2004-12-22 Ono Pharmaceutical Co COMPOUNDS DERIVED FROM CARBOXYLIC ACID AND MEDICAMENTS COMPRISING SUCH COMPOUNDS AS ACTIVE INGREDIENT
MXPA04002397A (es) 2001-09-14 2004-12-02 Methylgene Inc Inhibidores de histona deacetilasa.
US7868204B2 (en) 2001-09-14 2011-01-11 Methylgene Inc. Inhibitors of histone deacetylase
US6821502B2 (en) * 2002-06-12 2004-11-23 Chevron U.S.A. Inc. Method of making aluminum-containing zeolite with IFR structure
ES2444550T3 (es) 2002-08-29 2014-02-25 Temple University - Of The Commonwealth System Of Higher Education Arilpropenamidas y heteroarilpropenamidas, derivados de las mismas y usos terapéuticos de las mismas
GB0226855D0 (en) 2002-11-18 2002-12-24 Queen Mary & Westfield College Histone deacetylase inhibitors
US8362017B2 (en) 2003-08-29 2013-01-29 Exelixis, Inc. C-kit modulators and methods of use
US20080242681A1 (en) 2004-01-22 2008-10-02 Altana Pharma Ag N-4-(6-(Hetero)Aryl-Pyrimidin-4-Ylaminophenyl)-Benzenesulfonamides as Kinase Inhibitors
AR047541A1 (es) * 2004-02-13 2006-01-25 Sandoz Ag Fosfato de 5-[[4-[2-metil-2-piridinil-amino-etoxi]fenil]metil]-2,4 tiazolidinadiona (rosiglitazona) y sus formas polimorficas
US20050197336A1 (en) 2004-03-08 2005-09-08 Miikana Therapeutics Corporation Inhibitors of histone deacetylase
ES2430371T3 (es) 2004-03-11 2013-11-20 4Sc Ag Sulfonilpirroles como inhibidores de HDAC
US7345043B2 (en) 2004-04-01 2008-03-18 Miikana Therapeutics Inhibitors of histone deacetylase
US7351833B2 (en) * 2004-07-23 2008-04-01 Abbott Laboratories (1S,5S)-3-(5,6-dichloropyridin-3-yl)-3,6-diazabicyclo[3.2.0]heptane benzenesulfonate
US8436176B2 (en) * 2004-12-30 2013-05-07 Medicis Pharmaceutical Corporation Process for preparing 2-methyl-1-(2-methylpropyl)-1H-imidazo[4,5-c][1,5]naphthyridin-4-amine
PT1861365E (pt) 2005-03-15 2009-09-22 4Sc Ag N-sulfonilpirroles e a sua utilização como inibidores de histona-desacetilase
ATE510821T1 (de) * 2005-04-07 2011-06-15 4Sc Ag Sulfonylpyrrole als histondeacetylaseinhibitoren
UA91546C2 (uk) * 2005-05-03 2010-08-10 Бьорінгер Інгельхайм Інтернаціональ Гмбх КРИСТАЛІЧНА ФОРМА 1-ХЛОР-4-(β-D-ГЛЮКОПІРАНОЗ-1-ИЛ)-2-[4-((S)-ТЕТРАГІДРОФУРАН-3-ІЛОКСИ)-БЕНЗИЛ]-БЕНЗОЛУ, СПОСІБ ЇЇ ОДЕРЖАННЯ ТА ЇЇ ЗАСТОСУВАННЯ ПРИ ПРИГОТУВАННІ ЛІКАРСЬКИХ ЗАСОБІВ
MY152185A (en) * 2005-06-10 2014-08-29 Novartis Ag Modified release 1-[(3-hydroxy-adamant-1-ylamino)-acetyl]-pyrrolidine-2(s)-carbonitrile formulation
ZA200801890B (en) * 2005-08-29 2009-11-25 Sanofi Aventis Us Llc Novel crystalline form of a pyridazino (4, 5-B) indole derivative
JP2008522983A (ja) * 2005-09-13 2008-07-03 シコール インコーポレイティド ロクロニウムブロミドの合成方法
NZ566074A (en) 2005-09-21 2011-08-26 4Sc Ag Novel sulphonylpyrroles as inhibitors of HDAC's
BRPI0717554A2 (pt) * 2006-09-28 2013-10-29 Merck & Co Inc Composição farmacêutica, método para tratar câncer e aliviar os efeitos colaterais do inibidor da hdac, e, método de se obter um complexo de quelato inibidor da hdac de metal
US7837978B2 (en) * 2006-10-13 2010-11-23 Chevron U.S.A. Inc. Process for preparing aluminum-containing molecular sieve SSZ-26
PE20081506A1 (es) * 2006-12-12 2008-12-09 Infinity Discovery Inc Formulaciones de ansamicina
CN101778855A (zh) * 2007-05-22 2010-07-14 阿尔迪默菲克斯技术有限责任公司 替诺福韦酯半富马酸共晶体
TW200944520A (en) * 2008-01-29 2009-11-01 Glaxo Group Ltd Spiro compounds as NPY Y5 receptor antagonists

Also Published As

Publication number Publication date
JP5305909B2 (ja) 2013-10-02
KR20080046730A (ko) 2008-05-27
BRPI0616040A2 (pt) 2011-06-07
JP2009508825A (ja) 2009-03-05
TWI382971B (zh) 2013-01-21
WO2007039403A1 (en) 2007-04-12
EA200800791A1 (ru) 2009-04-28
EP1928826B1 (en) 2013-04-24
AR055647A1 (es) 2007-08-29
US20090297473A1 (en) 2009-12-03
IL189781A0 (en) 2008-08-07
CN101287706A (zh) 2008-10-15
CA2622670A1 (en) 2007-04-12
EP1928826A1 (en) 2008-06-11
NZ566073A (en) 2011-08-26
TW200745027A (en) 2007-12-16
KR101314158B1 (ko) 2013-10-04
ZA200801351B (en) 2009-09-30
EA018698B1 (ru) 2013-10-30
AU2006298881A1 (en) 2007-04-12
US8188138B2 (en) 2012-05-29

Similar Documents

Publication Publication Date Title
NO20081796L (no) Sulfonylpyrrolhydrokloridsalter som histondeacetylaseinhibitorer
EA200800700A1 (ru) Новые сульфонилпирролы как ингибиторы гдац (гистондезацетилазы)
NO20075051L (no) Nye sulfonylpyrroler og deres anvendelse som histon-deacetylaseinhibitorer
NZ594597A (en) Substituted piperidines as ccr3 antagonists
EA200901514A1 (ru) Новая сольватная и кристаллическая форма производных карбамоилциклогексана
WO2007056517A3 (en) Pharmaceutical salts and polymorphs of n- (5-chl0r0-2-pyridinyl) -2- [ [4- [ (dimethylamino) iminomethyl] benzoyl] amino] -5-meth oxy-benzamide, a factor xa inhibitor
CY1113547T1 (el) Διαδικασια συνθεσης ενωσεων χρησιμων στην αντιμετωπιση της ηπατιτιδας c
UY30842A1 (es) Derivados de n-(amino-heteroaril)-1h-pirrolopiridin-2-carboxamidas, su preparacion y su aplicacion en terapéutica
NO20083669L (no) 4-aryl-2amino-pyrimidiner eller 4-aryl-2-aminoalkylpyrimidiner som jak-2-modulatorer og fremgangsmater for anvendelse derav
WO2010009139A3 (en) Imidazolylpyrimidine compounds as hdac and / or cdk inhibitors
NO20071242L (no) Triazolpyridinylsulfanylderivater som P38-MAP-kinaseinhibitorer
NO20082209L (no) Homo- og heterocykliske forbindelser anvendbare som CETP-inhibitorer
CY1114662T1 (el) Ημιφουμαρικο αλας του 1-[4-[1-(4-κυκλοεξυλο-3-τριφθορομεθυλο-βενζυλοξυιμινο)-αιθυλο]-2-αιθυλο-βενζυλο]-αζετιδινο-3-καρβοξυλικου οξεος
PE20110062A1 (es) N-(3-(3,5-dimetoxifenetil)-1h-pirazol-5-il)-4-(3,4-dimetilpiperazin-1-il)benzamida y sales del mismo
NZ590285A (en) Heteroaryl derivatives as dgat1 inhibitors
NO20072605L (no) Nytt antranilinsyrederivat eller et salt derav
ATE557024T1 (de) Piperidinverbindungen als gpcr-agonisten
CY1116043T1 (el) Κρυσταλλικες μορφες υδροχλωρικου αλατος (4α-r,9α-s)-1-(1η-βενζοϊμιδαζολο-5-καρβονυλ)2,3,4,4α,9,9α-εξαϋδρο-1η-ινδενο[2,1-β]πυριδινο-6-καρβονιτριλιου και χρηση τους ως αναστολεις της hsd 1
BRPI0922457A2 (pt) forma polimórfica de ácido 1-(4-{1-[(e)-4-ciclo-hexil-3-trifluormetil-benziloxi-imino]-etil)-2-etil-benzil)-azetidino-3-carboxílico"
NO20055568L (no) Substituerte 1,4-diazepiner og anvendelser derav
MX2010006063A (es) Derivados de 4-bencil-amino-pirrolidina 1,2-disustituida como inhibidores de la proteina de transferencia de colesteril-ester (cetp) utiles para el tratamiento de las enfermedades tales como hiperlipidemia o arterioesclerosis.
PE20090243A1 (es) Compuestos de imidazol sustituido como inhibidores de renina
NO20091463L (no) Heterocyklisk deriverte metalloproteaseinhibitorer
NO20082118L (no) Heterocykliske CETP-inhibitorer
NO20083068L (no) Optisk aktive karbamater, fremgangsmate for deres fremstilling og anvendelse derav som farmasoytiske mellomprodukter

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application